OpGen Inc (NASDAQ:OPGN) shares saw unusually-high trading volume on Wednesday . Approximately 6,556,787 shares changed hands during mid-day trading, an increase of 352% from the previous session’s volume of 1,451,920 shares.The stock last traded at $0.33 and had previously closed at $0.30.
OPGN has been the subject of several research reports. Zacks Investment Research downgraded OpGen from a “buy” rating to a “hold” rating in a research report on Saturday, August 26th. HC Wainwright set a $1.00 target price on OpGen and gave the company a “buy” rating in a research report on Tuesday, July 18th. Finally, Dawson James reaffirmed a “buy” rating on shares of OpGen in a research report on Monday, June 19th.
The company has a 50-day moving average price of $0.30 and a 200 day moving average price of $0.30. The company’s market capitalization is $17.07 million.
In related news, Chairman Jven Capital, Llc bought 1,875,000 shares of the stock in a transaction dated Tuesday, July 18th. The stock was acquired at an average price of $0.40 per share, for a total transaction of $750,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Timothy C. Dec bought 65,000 shares of the stock in a transaction dated Tuesday, July 18th. The stock was bought at an average price of $0.40 per share, with a total value of $26,000.00. Following the purchase, the chief financial officer now owns 118,966 shares of the company’s stock, valued at approximately $47,586.40. The disclosure for this purchase can be found here. 31.83% of the stock is currently owned by company insiders.
A hedge fund recently raised its stake in OpGen stock. Vanguard Group Inc. increased its stake in OpGen Inc (NASDAQ:OPGN) by 1.6% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 342,860 shares of the medical research company’s stock after buying an additional 5,500 shares during the quarter. Vanguard Group Inc. owned about 1.25% of OpGen worth $219,000 as of its most recent filing with the SEC. Institutional investors own 8.13% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://www.com-unik.info/2017/10/11/opgen-inc-opgn-sees-unusually-high-trading-volume.html.
OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.
What are top analysts saying about OpGen Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for OpGen Inc and related companies.